Insmed (NASDAQ:INSM) Incorporated (NASDAQ:INSM) is a biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company’s expertise lies in inhaled and systemic drug-delivery technologies designed to target diseases with high unmet medical needs. Insmed’s lead product, Arikayce® (amikacin liposome inhalation suspension), is the first and only FDA-approved therapy for refractory Mycobacterium avium complex (MAC) lung disease in adults, representing a significant advance in treating this life-threatening pulmonary condition.
Arikayce, administered via nebulizer, employs liposomal encapsulation to deliver high concentrations of antibiotic directly to the site of infection while minimizing systemic exposure. Initially approved in the United States, the product has since received marketing authorizations in Europe, Canada, Japan and Australia, establishing Insmed’s footprint in key global markets. The company works closely with pulmonologists, infectious disease specialists and patient advocacy groups to support disease awareness, diagnosis and access to therapy.
Beyond Arikayce, Insmed maintains a growing pipeline of investigational therapies targeting serious rare diseases in pulmonology, nephrology and genetic disorders. Its research programs leverage proprietary delivery platforms and robust preclinical models to advance novel candidates toward regulatory milestones. Collaborations with academic institutions and industry partners further enhance Insmed’s ability to expand its portfolio and address additional high-impact indications.
Founded in 2005 and headquartered in Bridgewater, New Jersey, Insmed operates research, development and commercial teams across the United States and Europe. Under the leadership of President and Chief Executive Officer Will Lewis, the company emphasizes patient-centric innovation, rigorous clinical science and strategic regulatory planning. Insmed’s global organization continues to grow, fostering a network of experts committed to improving outcomes for patients affected by rare and serious diseases.
